tacrolimus and Plasmacytoma

tacrolimus has been researched along with Plasmacytoma* in 4 studies

Reviews

1 review(s) available for tacrolimus and Plasmacytoma

ArticleYear
Post-transplant lymphoproliferative disorder presenting as multiple myeloma.
    American journal of hematology, 2010, Volume: 85, Issue:8

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diabetic Nephropathies; Disease Progression; Epstein-Barr Virus Infections; Fatal Outcome; Ganciclovir; Humans; Immunosuppressive Agents; Kidney Transplantation; Lumbar Vertebrae; Lymphoproliferative Disorders; Male; Middle Aged; Multiple Myeloma; Mycophenolic Acid; Pancreas Transplantation; Plasmacytoma; Postoperative Complications; Prednisone; Reoperation; Rituximab; Spinal Neoplasms; Tacrolimus; Thalidomide

2010

Other Studies

3 other study(ies) available for tacrolimus and Plasmacytoma

ArticleYear
[A case report of cutaneous plasmacytosis].
    Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences, 2018, Aug-18, Volume: 50, Issue:4

    A collection of plasma cells in the skin can represent a broad spectrum of disease entities. Secondary syphilis, primary cutaneous plasmacytoma, primary cutaneous plasmacytosis, cutaneous lymphoid hyperplasia and nodular amyloidosis are considered possible differential diagnoses. The primary cutaneous plasma cell disorders can range from malignant to benign plasma cell neoplasms. The malignant conditions are neoplastic diseases having monoclonal proliferations, rapid progression and fatal outcome while the benign plasma cell disorders usually show polyclonality, chronicity and benign process, including plasmacytosis. We present a case of cutaneous plasmacytosis. The patient was a 34-year-old man, presented with disseminated reddish-brown plaques and nodules on the right side of the hips, inguinal groove, and the thigh. Histopathologically, mature plasma cells perivascular infiltrates were observed mainly in the dermis. Polyclonality of infiltrating plasma cells with coexistence of both kappa and gamma chain-positive cells demonstrated with immunohistochemistry, as well as CD20+++, CD38++++, CD79a++++, CD138++, Ki67<30%. The diagnosis, cutaneous plasmacytosis, was established by the pertinent laboratory findings. Primary cutaneous plasmacytosis was an uncommon reactive lymphoplasmacytic disorder of uncertain etiology. Cutaneous plasmacytosis is a rare disease characterized by peculiar multiple eruptions and hyper gamma globulinemia. It has been mainly described in patients of Japanese descent, with only few reports in Caucasians and Chinese, although information concerning the disorder was limited to individual case reports. Cutaneous plasmacytosis is a rare disorder, which is characterized by multiple red to dark-brown nodules and plaques on the trunk and usually associated with polyclonal hyper gamma globulinaemia. Primary cutaneous plasmacytosis or cutaneous plasmacytosis was thought to be a reactive process with unknown etiology. Histologically, lesions contain dense perivascular infiltration of mature polyclonal plasma cells without any atypia, in the dermis and subcutaneous fat. The clinical course is chronic and benign without spontaneous remission. Available treatments for cutaneous plasmacytosis include psoralen ultraviolet A radiotherapy, systemic chemotherapy and intralesional steroid injection. The patient with cutaneous plasmacytosis in this report was treated with tacrolimus ointment and psoralen ultraviolet A.

    Topics: Adult; Humans; Hyperplasia; Immunosuppressive Agents; Male; Plasma Cells; Plasmacytoma; Skin; Skin Diseases; Tacrolimus

2018
Targeting T cells to hit B cells: successful treatment of cutaneous plasmacytosis with topical pimecrolimus.
    Dermatology (Basel, Switzerland), 2006, Volume: 213, Issue:2

    Cutaneous plasmacytosis is a rare disease predominantly found in Japanese patients. We describe the case of a 75-year-old white female with cutaneous plasmacytosis of the face and involvement of the bone marrow. In contrast to other cases of cutaneous plasmacytosis, the patient revealed hypogammaglobulinemia and elevated levels of free light chains in the urine. Treatment with topical pimecrolimus 1%, which primarily targets T cells, led to almost complete clinical and histological remission of the skin lesions. Our report indicates that the therapeutically induced disappearance of the plasma cells was due to indirect T-cell-mediated effects.

    Topics: Aged; B-Lymphocytes; Biopsy; Calcineurin Inhibitors; Female; Follow-Up Studies; Humans; Plasmacytoma; Skin Neoplasms; T-Lymphocytes; Tacrolimus

2006
Treatment of facial lesion of cutaneous plasmacytosis with tacrolimus ointment.
    Journal of the American Academy of Dermatology, 2003, Volume: 49, Issue:6

    Topics: Facial Dermatoses; Humans; Immunosuppressive Agents; Male; Middle Aged; Ointments; Plasmacytoma; Skin Neoplasms; Tacrolimus

2003